Azora Therapeutics, Inc. (NASDAQ: AZR) Stock Competitors & Peer Comparison

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, RPRX has a market cap of 29.6B. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while RPRX trades at $66.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas RPRX's P/E ratio is 12.67. In terms of profitability, AZR's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, AZR is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for AZR.Check RPRX's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas WBA's P/E ratio is -1.64. In terms of profitability, AZR's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, AZR is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for AZR.Check WBA's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, CORT has a market cap of 8.7B. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while CORT trades at $80.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas CORT's P/E ratio is 229.89. In terms of profitability, AZR's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, AZR is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for AZR.Check CORT's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, KNSA has a market cap of 7.1B. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while KNSA trades at $90.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas KNSA's P/E ratio is 69.77. In terms of profitability, AZR's ROE is N/A, compared to KNSA's ROE of +0.17%. Regarding short-term risk, AZR is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for AZR.Check KNSA's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while LQDA trades at $41.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas LQDA's P/E ratio is 30.55. In terms of profitability, AZR's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, AZR is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for AZR.Check LQDA's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while PBH trades at $49.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas PBH's P/E ratio is 11.26. In terms of profitability, AZR's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, AZR is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for AZR.Check PBH's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas HROWL's P/E ratio is N/A. In terms of profitability, AZR's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, AZR is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for AZR.Check HROWL's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas HROWM's P/E ratio is N/A. In terms of profitability, AZR's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, AZR is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for AZR.Check HROWM's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, LTGO has a market cap of 811.5M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while LTGO trades at $13.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas LTGO's P/E ratio is -5.35. In terms of profitability, AZR's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, AZR is more volatile compared to LTGO. This indicates higher risk in terms of short-term price fluctuations for AZR.Check LTGO's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, HELP has a market cap of 545.5M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while HELP trades at $8.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas HELP's P/E ratio is -2.11. In terms of profitability, AZR's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, AZR is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for AZR.Check HELP's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas SVA's P/E ratio is -5.68. In terms of profitability, AZR's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, AZR is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for AZR.Check SVA's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, CUVL has a market cap of 249.9M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while CUVL trades at $4.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas CUVL's P/E ratio is 10.68. In terms of profitability, AZR's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, AZR is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for AZR.Check CUVL's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, HITI has a market cap of 230.9M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while HITI trades at $2.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas HITI's P/E ratio is -9.57. In terms of profitability, AZR's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, AZR is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for AZR.Check HITI's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, CELG-RI has a market cap of 194.1M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while CELG-RI trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AZR's ROE is N/A, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, AZR is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for AZR.Check CELG-RI's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, ETRA has a market cap of 155.1M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while ETRA trades at $7.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas ETRA's P/E ratio is -2.76. In terms of profitability, AZR's ROE is N/A, compared to ETRA's ROE of N/A. Regarding short-term risk, AZR is more volatile compared to ETRA. This indicates higher risk in terms of short-term price fluctuations for AZR.Check ETRA's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, TRXB has a market cap of 114.4M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while TRXB trades at $13.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas TRXB's P/E ratio is -5.56. In terms of profitability, AZR's ROE is N/A, compared to TRXB's ROE of N/A. Regarding short-term risk, AZR is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for AZR.Check TRXB's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas ATLN's P/E ratio is -0.68. In terms of profitability, AZR's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, AZR is more volatile compared to ATLN. This indicates higher risk in terms of short-term price fluctuations for AZR.Check ATLN's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, CTOR has a market cap of 55.2M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while CTOR trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas CTOR's P/E ratio is -1.26. In terms of profitability, AZR's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, AZR is more volatile compared to CTOR. This indicates higher risk in terms of short-term price fluctuations for AZR.Check CTOR's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, RTSN has a market cap of 43.6M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while RTSN trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas RTSN's P/E ratio is -4.45. In terms of profitability, AZR's ROE is N/A, compared to RTSN's ROE of N/A. Regarding short-term risk, AZR is more volatile compared to RTSN. This indicates higher risk in terms of short-term price fluctuations for AZR.Check RTSN's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas RAD's P/E ratio is -0.05. In terms of profitability, AZR's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, AZR is more volatile compared to RAD. This indicates higher risk in terms of short-term price fluctuations for AZR.Check RAD's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas GLTO's P/E ratio is -1.78. In terms of profitability, AZR's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, AZR is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for AZR.Check GLTO's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, COSM has a market cap of 31.1M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while COSM trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas COSM's P/E ratio is -0.42. In terms of profitability, AZR's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, AZR is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for AZR.Check COSM's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, NSRX has a market cap of 27.6M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while NSRX trades at $3.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas NSRX's P/E ratio is -4.44. In terms of profitability, AZR's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, AZR is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for AZR.Check NSRX's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, SCYX has a market cap of 24M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while SCYX trades at $3.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas SCYX's P/E ratio is -1.11. In terms of profitability, AZR's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, AZR is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for AZR.Check SCYX's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, POM has a market cap of 16.4M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while POM trades at $1.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas POM's P/E ratio is -0.28. In terms of profitability, AZR's ROE is N/A, compared to POM's ROE of +0.80%. Regarding short-term risk, AZR is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for AZR.Check POM's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, BFRI has a market cap of 13M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while BFRI trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas BFRI's P/E ratio is -1.59. In terms of profitability, AZR's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, AZR is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for AZR.Check BFRI's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, CNSY has a market cap of 12.9M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while CNSY trades at $1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas CNSY's P/E ratio is -0.41. In terms of profitability, AZR's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, AZR is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for AZR.Check CNSY's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas CJJD's P/E ratio is -0.46. In terms of profitability, AZR's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, AZR is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for AZR.Check CJJD's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas SSY's P/E ratio is -2.86. In terms of profitability, AZR's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, AZR is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for AZR.Check SSY's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, SCNX has a market cap of 5.3M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while SCNX trades at $3.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas SCNX's P/E ratio is -1.54. In terms of profitability, AZR's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, AZR is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for AZR.Check SCNX's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, BGMS has a market cap of 5M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while BGMS trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas BGMS's P/E ratio is -0.25. In terms of profitability, AZR's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, AZR is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for AZR.Check BGMS's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas MDVL's P/E ratio is -0.05. In terms of profitability, AZR's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, AZR is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for AZR.Check MDVL's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, EOCN has a market cap of 2.8M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while EOCN trades at $2.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas EOCN's P/E ratio is -0.19. In terms of profitability, AZR's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, AZR is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for AZR.Check EOCN's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, PAVS has a market cap of 2.7M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while PAVS trades at $3.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas PAVS's P/E ratio is -0.03. In terms of profitability, AZR's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, AZR is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for AZR.Check PAVS's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas ATNFW's P/E ratio is N/A. In terms of profitability, AZR's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, AZR is more volatile compared to ATNFW. This indicates higher risk in terms of short-term price fluctuations for AZR.Check ATNFW's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, AZR's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, AZR is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for AZR.Check BGMSP's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas AZNH's P/E ratio is 38.35. In terms of profitability, AZR's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, AZR is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for AZR.Check AZNH's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, ASBP has a market cap of 842.2K. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while ASBP trades at $7.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas ASBP's P/E ratio is -0.31. In terms of profitability, AZR's ROE is N/A, compared to ASBP's ROE of +19.93%. Regarding short-term risk, AZR is more volatile compared to ASBP. This indicates higher risk in terms of short-term price fluctuations for AZR.Check ASBP's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, BFRIW has a market cap of 796.7K. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while BFRIW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas BFRIW's P/E ratio is N/A. In terms of profitability, AZR's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, AZR is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for AZR.Check BFRIW's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, AZR's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, AZR is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for AZR.Check LFLYW's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, ASBPW has a market cap of 149.5K. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while ASBPW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas ASBPW's P/E ratio is N/A. In terms of profitability, AZR's ROE is N/A, compared to ASBPW's ROE of +19.93%. Regarding short-term risk, AZR is less volatile compared to ASBPW. This indicates lower risk in terms of short-term price fluctuations for AZR.Check ASBPW's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, PRPH has a market cap of 91.1K. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while PRPH trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas PRPH's P/E ratio is N/A. In terms of profitability, AZR's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, AZR is more volatile compared to PRPH. This indicates higher risk in terms of short-term price fluctuations for AZR.Check PRPH's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, OREX has a market cap of 0. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas OREX's P/E ratio is -0.14. In terms of profitability, AZR's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, AZR is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for AZR.Check OREX's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas ESRX's P/E ratio is 10.69. In terms of profitability, AZR's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, AZR is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for AZR.Check ESRX's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, POZN has a market cap of 0. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas POZN's P/E ratio is N/A. In terms of profitability, AZR's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, AZR is more volatile compared to POZN. This indicates higher risk in terms of short-term price fluctuations for AZR.Check POZN's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas IPXL's P/E ratio is -10.11. In terms of profitability, AZR's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, AZR is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for AZR.Check IPXL's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas SHPG's P/E ratio is 11.35. In terms of profitability, AZR's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, AZR is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for AZR.Check SHPG's competition here

Azora Therapeutics, Inc. (NASDAQ: AZR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AZR stands at 10.4M. In comparison, CPD has a market cap of 0. Regarding current trading prices, AZR is priced at $3.89 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AZR currently has a P/E ratio of -0.24, whereas CPD's P/E ratio is N/A. In terms of profitability, AZR's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, AZR is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for AZR.Check CPD's competition here